Back to NVSEFView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA7/26/2018
Aimovig
Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
FingolimodPhase 3
Multiple Sclerosis
dovitinibPhase 3
Solid Tumors
MF59-eH1N1_fPhase 3
Influenza
Glycopyrronium bromidePhase 3
Chronic Obstructive Pulmonary Disease
Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccinePhase 3
Swine-Origin Influenza A H1N1 Virus
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts